Moderna has dosed the first participant in a Phase 1 trial of its Nipah virus vaccine candidate, mRNA-1215, that has been developed in collaboration with the US National Institutes of Health (NIH).
Moderna announced today that it is expanding its pipeline of innovative vaccines with three new development programs based on the 'clinical success' of its infectious disease vaccine portfolio to date.
